Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,526.00
Bid: 1,525.50
Ask: 1,526.00
Change: -73.50 (-4.60%)
Spread: 0.50 (0.033%)
Open: 1,503.50
High: 1,532.00
Low: 1,484.00
Prev. Close: 1,599.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Business Leaders Warn Brexit Would "Deter Investment, Threaten Jobs"

Tue, 23rd Feb 2016 11:58

LONDON (Alliance News) - A group of more than 100 leaders of major businesses on Tuesday backed Prime Minister David Cameron's campaign for Britain to remain in the EU, saying a British exit, or Brexit, would "deter investment and threaten jobs."

"Business needs unrestricted access to the European market of 500 million people in order to continue to grow, invest and create jobs," the business leaders said in a letter published in the Times.

"We believe that leaving the EU would deter investment, threaten jobs and put the economy at risk," the letter read.

The nearly 200 signatories included top executives from 36 companies listed on London's FTSE 100 index.

Among the companies represented are Airbus UK, British Telecom, BP, Diageo, EasyJet, Goldman Sachs International, GlaxoSmithKline, HSBC, Rio Tinto, Rolls Royce, Royal Dutch Shell, Ryanair, SABMiller, Siemens Manufacturing, Standard Chartered, Virgin Media and Vodafone.

"The businesses we lead represent every sector and region of the UK," they wrote. "Together we employ hundreds of thousands of people across the country."

Cameron's deal with the 27 other EU leaders last week means "Britain is better off staying in a reformed EU," they added, highlighting agreements to reduce bureaucracy, deepen the single market and pursue international trade deals.

The Confederation of British Industry, which represents some 190,000 businesses, has also backed Cameron, praising the EU reform package as "a major step forward."

Britain will conduct a referendum on June 23 on whether or not to remain part of the EU.

Eurosceptics inside Cameron's ruling Conservative party have provided the strongest support for the "leave" campaign.

Copyright dpa

More News
Today 17:25

European shares subdued ahead of economic data, French elections; H&M plunges

H&M tumbles after missing quarterly profit forecasts

*

Read more
Today 17:02

London's FTSE 100 slips as investors eye US, UK economic data

FTSE 100 down 0.6%, FTSE 250 adds 0.2%

*

Read more
Today 16:40

GSK shares slide after US health agency narrows scope of RSV shots

GSK shares fall as much as 7%

*

Read more
Today 15:48

London close: Stocks mixed ahead of key UK, US data

(Sharecast News) - London stocks ended Thursday's trading session with a mixed performance as market participants awaited crucial US inflation data and UK GDP figures set to be released later in the week.

Read more
Today 12:05

LONDON MARKET MIDDAY: Tepid trade as eyes on elections, US inflation

(Alliance News) - Stock prices in Europe struggled to make headway heading into Thursday afternoon, with sentiment cautious on the penultimate trading day of the quarter.

Read more
Today 09:58

GSK shares drop as US narrows recommendations for RSV vaccines

(Sharecast News) - Shares in biopharma giant GSK tumbled on Thursday after a ruling by a US health agency narrowed usage recommendations for all respiratory syncytial virus (RSV) vaccines, restricting the addressable market for the company's Arexvy product.

Read more
Today 09:00

LONDON MARKET OPEN: Nervy trade in London before US data

(Alliance News) - Stock prices in London opened lower on Thursday, despite peers in Europe climbing, with some of the FTSE 100 heavyweights in decline in early trade.

Read more
26 Jun 2024 22:50

US CDC narrows age recommendation for RSV shots in US

June 26 (Reuters) - The U.S. CDC on Wednesday narrowed its recommendation for use of respiratory syncytial virus vaccines in older adults this year and held off on recommending their use for adults under age 60.

Read more
26 Jun 2024 11:00

US advisers to consider RSV shots as GSK looks to keep market lead

June 26 (Reuters) - A committee of outside experts to the U.S. CDC are set to vote on whether to expand the age group of adults who should receive respiratory syncytial virus (RSV) vaccines this year, as GSK battles rival Pfizer and new entrant Moderna to keep its top position in the market.

Read more
25 Jun 2024 08:25

Merck KGaA shares plunge after cancer drug hopeful fails

FRANKFURT, June 25 (Reuters) - Shares in Germany's Merck KGaA slumped 8.9% at the open on Tuesday after the diversified group late on Monday said a trial testing a head and neck cancer drug, previously seen as promising, would be stopped for lack of efficacy.

Read more
24 Jun 2024 08:55

TOP NEWS: GSK hails Omjjara approval in Japan; Jemperli review in EU

(Alliance News) - GSK PLC on Monday said it has landed an approval in Japan and also highlighted regulatory progress in the EU.

Read more
24 Jun 2024 07:43

LONDON BRIEFING: Prudential announces buyback; Frasers and THG in deal

(Alliance News) - London's FTSE 100 is called to open lower at the start of the week, with share price falls for major US tech shares, Nvidia included, spooking investors on this side of the Atlantic.

Read more
24 Jun 2024 07:21

GSK reports regulatory progress for Omjjara, Jemperli

(Sharecast News) - GSK announced on Monday that it has received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for 'Omjjara', or momelotinib, as a treatment for myelofibrosis.

Read more
20 Jun 2024 16:01

Industry groups back drugmakers' appeal in Zantac cancer lawsuits

June 20 (Reuters) - A bid by GSK and other drugmakers to stop more than 70,000 lawsuits in Delaware over discontinued heartburn drug Zantac has received the backing of leading U.S. industry groups, including the United States Chamber of Commerce and Pharmaceutical Research and Manufacturers of America.

Read more
11 Jun 2024 14:31

Zantac litigation fears overdone at GSK, says Shore Capital

(Sharecast News) - Volatile moves in GSK's share price are likely to persist in the near term as a result of ongoing Zantac-related litigation, but the long-term investment case is "still appealing", according to Shore Capital, which kept a 'buy' rating on the stock.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.